Document Classification

Section Type: RESULTS

Text: After one year of treatment, compared to the baseline the nateglinide group showed a significant reduction in HbA1c (-21 %, p < 0. 01), FPG (-20. 7 %), p < 0. 01, PPG (-21. 5 %, p < 0. 05), HOMA index (-25. 4 %, p < 0. 05) ; the glibenclamide group, showed a significant reduction in HbA1c (-11 %, p < 0. 05), FPG (-23. 2 %, p < 0. 05), PPG (-11. 2 %, p < 0. 05), and HOMA index (-23. 9 %, p < 0. 05) but to a minor extent.